display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic-recurrent HNSCC (mHNSCC)metastatic/advanced hepatocellular cancer (mHCC)
hepatocell cancer (HCC)mHCC - (neo)adjuvant (NA)mHCC - 1st line (L1)
sintilimab based treatment
sintilimab Wang Wang ORIENT-32

Study type: